Fig. 5: ddPCR quantification of MyHC gene expression in treated muscles.

a Using ddPCR, we quantified gene expression of Myh2 (left; MyHC type 2 A), Myh1 (middle; MyHC Type X), and Myh4 (MyHC Type 2B) as copies/µl cDNA in TA muscles of LR41;Mbnl1−/− (N = 10) and LR20b (N = 4) mice treated with Clcn1 ASO (+) or invert oligo (−) for 16, 18, or 52 days. Untreated wild-type (WT; N = 5) TA muscles served as controls. b Using the copies/µl data in a), we calculated the percentage (%) of total myosin transcripts for Myh2 (left), Myh1 (middle), and Myh4 (right) of LR41;Mbnl1−/− (N = 10), LR20b (N = 4), and WT (N = 4). c Relationship of ddPCR quantification of Clcn1 exon 7a inclusion (x-axis; see Fig. 2) with percentage of Myh2, Myh1, and Myh4 (y-axis) in individual samples of LR41;Mbnl1−/− (N = 10) and WT (N = 4). The Pearson correlation coefficient r and P-value for each are shown. d Quantification of embryonic myosin Myh3 (MyHC-emb) gene expression, a marker of muscle regeneration, in LR41;Mbnl1−/− (N = 10), LR20b (N = 4), and WT (N = 5). e Myh3 expression as percentage of total myosin gene expression in LR41;Mbnl1−/− (N = 10), LR20b (N = 4), and WT (N = 5). f Relationship of ddPCR quantification of Clcn1 exon 7a inclusion (x-axis) with Myh3 as percentage of total myosin (y-axis) in individual samples of LR41;Mbnl1−/− (N = 10) and WT (N = 4). The Pearson correlation coefficient r and P-value for each are shown. ****P < 0.0001; ***P < 0.001; **P < 0.01; *P < 0.05 (one-way ANOVA). Error bars indicate ±s.e.m. Source data are provided as a Source Data file.